{
    "Trade/Device Name(s)": [
        "Clungene Amphetamine Tests",
        "Clungene Cocaine Tests",
        "Clungene Oxazepam Tests"
    ],
    "Submitter Information": "Hangzhou Clongene Biotech Co., Ltd.",
    "510(k) Number": "K161251",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052115"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "DIO",
        "JXM"
    ],
    "Summary Letter Date": "July 22, 2016",
    "Summary Letter Received Date": "July 27, 2016",
    "Submission Date": "August 29, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.3100",
        "21 CFR 862.3170",
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system",
        "Benzodiazepine test system",
        "Cocaine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "d-Amphetamine",
        "Cocaine",
        "Oxazepam"
    ],
    "Specimen Type(s)": [
        "Human urine"
    ],
    "Specimen Container(s)": [
        "Cassette",
        "Cup",
        "Dip Card",
        "Split Key Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow system",
        "Competitive binding"
    ],
    "Methodologies": [
        "Immunochemistry",
        "Lateral flow immunoassay"
    ],
    "Submission Type(s)": [
        "Cassette",
        "Cup",
        "Dip Card",
        "Split Key Cup"
    ],
    "Document Summary": "FDA 510(k) summary for Clungene Amphetamine, Cocaine, and Oxazepam qualitative immunochromatographic urine drug tests for OTC and prescription use",
    "Indications for Use Summary": "Qualitative detection of d-Amphetamine, Cocaine, or Oxazepam in human urine at respective cut-off concentrations; intended for over-the-counter and prescription use as a preliminary drug of abuse screen",
    "fda_folder": "Toxicology"
}